Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

C. Ola Landgren, Ajai Chari, Yael C. Cohen, Andrew Spencer, Peter Voorhees, Jane A. Estell, Irwindeep Sandhu, Matthew W. Jenner, Catherine Williams, Michele Cavo, Niels W.C.J. van de Donk, Meral Beksac, Philippe Moreau, Hartmut Goldschmidt, Steven Kuppens, Rajesh Bandekar, Pamela L. Clemens, Tobias Neff, Christoph Heuck, Ming QiCraig C. Hofmeister

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Fingerprint

Dive into the research topics of 'Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)'. Together they form a unique fingerprint.

Medicine & Life Sciences